Danaher (DHR) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Danaher (NYSE: DHR) recently:

• 12/23/2024 – Danaher is now covered by analysts at Scotiabank. They set a “sector perform” rating and a $265.00 price target on the stock.
• 12/19/2024 – Danaher is now covered by analysts at Guggenheim. They set a “buy” rating and a $275.00 price target on the stock.
• 12/14/2024 – Danaher was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 12/13/2024 – Danaher was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating. They now have a $290.00 price target on the stock.
• 12/5/2024 – Danaher was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/27/2024 – Danaher was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 11/18/2024 – Danaher was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/6/2024 – Danaher was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/31/2024 – Danaher was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating. They now have a $285.00 price target on the stock.

Danaher Stock Performance

Shares of DHR stock opened at $230.75 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company has a market capitalization of $166.66 billion, a price-to-earnings ratio of 44.04, a price-to-earnings-growth ratio of 4.33 and a beta of 0.83. Danaher Co. has a one year low of $222.53 and a one year high of $281.70. The company’s 50-day moving average is $242.22 and its 200 day moving average is $256.09.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.02 EPS. Sell-side analysts expect that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.47%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Benjamin Edwards Inc. boosted its stake in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after acquiring an additional 38 shares during the last quarter. Wedge Capital Management L L P NC boosted its position in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 38 shares during the last quarter. Abacus Planning Group Inc. raised its holdings in Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after acquiring an additional 40 shares during the last quarter. Certified Advisory Corp lifted its stake in shares of Danaher by 4.5% during the 2nd quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after purchasing an additional 40 shares during the period. Finally, Meridian Financial Partners LLC boosted its holdings in shares of Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.